Kallyope is a biotechnology and therapeutic microbiome company that was founded by Charles Zucker, Tom Maniatis, and Richard Axel in 2015 that is headquartered in New York City, New York. Kallyope uses gene sequencing, computational biology, neural imaging, cellular/molecular biology, and human genetics to understand the relationship between the human gut and the human brain in combination with their own drug discovery expertise to develop effective gut-brain therapies that improve human health and nutrition.
On December 10, 2015 Kallyope closed their series A funding round with $44 million in funding from The Column Group, Polaris Partners, Lux Capital, Illumina Ventures, Alexandria Venture investments, and Tony Evnin.
On February 22, 2018 Kallyope closed their series B funding round with $66 million in funding from Two Sigma Ventures, The Column Group, Polaris Partners, Lux Capital, Illumina Ventures, Euclidean Capital, and Alexandria Venture Investments.
SVP, Drug Discovery
VP, Business Development
Kallyope and Novo Nordisk Team Up To Tackle Obesity | BioSpace
Documentaries, videos and podcasts
- Microbiome and gut healthThe field of health as it relates to Gut microbiota - the microorganisms inside the human microbiome, including bacteria and archaea that live in the digestive tracts of humans.
- CompanyA company, abbreviated as "Co." within a company name, is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.
- BiotechnologyBiotechnology in a broad sense includes the use of living systems and organisms, as well as their parts for the development or production of products.